2cureX is an in-vitro diagnostics company founded in 2006 with the aim of matching patients to treatments and improving the way in which cancer care is delivered. 2cureX is headquartered in Copenhagen, Denmark, and has a research site in Hamburg, Germany.
Our Mission is “Improving patients’ outcomes by establishing individualized drug sensitivity profiling as routine practice in Oncology, so that all treatment decisions are supported by a personal test”.
FOCUSED ON CLINICAL USE
We are leaders in the use of patient-derived 3D tumoroids to assess the effect of drugs on individual patients and are committed to bringing this technology to routine clinical practice. To that end we have developed the IndiTreat® family of assays, with an initial focus in GI cancers.
The company is EN ISO 13485 certified.